Year: 2017
Type: article
Abstract: Incidence of candidiasis has increased in past decade. Epidemiology is reported shifting from albicans to non-albicans Candida (NAC) species like C. glabrata, which is intrinsically resistant to azole drugs. No newantifungal has come into practice from last decade. Rising resistance to existing antifungal (in clinical isolates ofCandida) have necessitated the need for new antifungals. New molecular drug targets need to be explored forthe development of novel antifungal drugs. The drug targets are oftenly the cellular proteins of variousmetabolic pathways (like ergosterol synthesis-, cell wall biogenesis-, calcium-calcineurin- and DNA checkpointpathways etc.), having no significant similarity with host proteins to overrule the possibility of side effects. Inthis review, some potential proteins of C. glabrata and their pathways are discussed in context to explore theirpotential as drug target for antifungal drug development.
Authors: Payal Gupta, Nishant Rai, Navin Kumar
Institution: Graphic Era University
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W3184728046